Home

James F Watson

CIK 1420406 · last filed 2018-01-29

James F Watson is a corporate insider who has filed 3 SEC Form 4 insider transactions across 3 companies since 2013. The most recent filing, for MNLO, was dated Jan 29, 2018. Across all open-market trades the lifetime net is −$66.3M, making them a net seller over the disclosed history. 17 SEC filings were submitted jointly with David J Collier.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

3

Total Filings

3

Lifetime Open-Market Net

-$66.29M

Filer Profile

Reported Address
C/O PRESIDIO PARTNERS
655 MONTGOMERY STREET, SUITE 6-161
SAN FRANCISCO, CA 94111
Related Filers
David J Collier — 17 joint filings, latest 2020-02-14
THOMAS R BARUCH — 11 joint filings, latest 2013-09-20
Presidio Partners 2007 (Parallel), L.P. — 8 joint filings, latest 2018-07-26
Presidio Partners 2007 GP, L.P. — 8 joint filings, latest 2018-07-26
Presidio Partners 2007, L.P. — 8 joint filings, latest 2018-07-26
Presidio Partners 2007 GP, LLC — 4 joint filings, latest 2016-04-20
VELOCITY PHARMACEUTICAL HOLDINGS LLC — 1 joint filings, latest 2020-02-14
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
VYNE Therapeutics Inc. (MNLO) Delisted 10%+ Owner 2,267,799 — — $0 1 2018-01-29
INTERMOLECULAR INC (IMI) Delisted 10%+ Owner 0 — — -$59.15M 1 2014-11-12
TETRAPHASE PHARMACEUTICALS INC (TTPH) Delisted 10%+ Owner 100,362 — — -$7.14M 1 2013-09-20

Recent Filings

3 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2018-01-29 VYNE Therapeutics Inc. (MNLO) Delisted Conv (C) +6,028,590 $0 EDGAR
2014-11-12 INTERMOLECULAR INC (IMI) Delisted Sell (S) −26,887,530 -$59.15M EDGAR
2013-09-20 TETRAPHASE PHARMACEUTICALS INC (TTPH) Delisted Sell (S) −700,000 -$7.14M EDGAR
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.